The role of AIB1 and PAX2 in primary breast cancer: validation of AIB1 as a negative prognostic factor.
(2013) In Annals of Oncology 24(5). p.1244-1252- Abstract
- BackgroundThe steroid-receptor coactivator amplified in breast cancer one (AIB1) is implicated to be a prognostic factor, although the results are not unanimous. Recently its effect was suggested to be modified by paired box 2 gene product (PAX2).Patients and methodsUsing immunohistochemistry (IHC) AIB1 and PAX2 were investigated in two cohorts of early breast cancer, including systemically untreated premenopausal lymph-node-negative women and pre- and postmenopausal women receiving tamoxifen.ResultsAIB1 scores were available for 490 patients and PAX2 scores were available for 463 patients. High AIB1 was a negative prognostic factor for distant disease-free survival (DDFS, P = 0.02) and overall survival (OS, P < 0.001) in systemically... (More)
- BackgroundThe steroid-receptor coactivator amplified in breast cancer one (AIB1) is implicated to be a prognostic factor, although the results are not unanimous. Recently its effect was suggested to be modified by paired box 2 gene product (PAX2).Patients and methodsUsing immunohistochemistry (IHC) AIB1 and PAX2 were investigated in two cohorts of early breast cancer, including systemically untreated premenopausal lymph-node-negative women and pre- and postmenopausal women receiving tamoxifen.ResultsAIB1 scores were available for 490 patients and PAX2 scores were available for 463 patients. High AIB1 was a negative prognostic factor for distant disease-free survival (DDFS, P = 0.02) and overall survival (OS, P < 0.001) in systemically untreated women, while no prognostic effect was seen in the tamoxifen-treated cohort, indicating AIB1 to be a predictor of tamoxifen response. In systemically untreated patients, PAX2 was not a prognostic factor, nor did it modify the effect of AIB1. However, in ER-positive patients receiving tamoxifen, PAX2 appeared to be a positive prognostic factor in premenopausal patients, while a negative factor in postmenopausal. The interaction between the menopausal status and PAX2 was significant (P = 0.01).ConclusionsIn an independent cohort of low-risk premenopausal patients, we validate AIB1 as a negative prognostic factor, indicating AIB1 to be an interesting target for new anti-cancer therapies. The effect of PAX2 warrants further studies. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/3347307
- author
- Alkner, Sara LU ; Bendahl, Po ; Grabau, Dorthe LU ; Malmström, Per LU ; Fernö, Mårten LU and Rydén, Lisa LU
- organization
- publishing date
- 2013
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Annals of Oncology
- volume
- 24
- issue
- 5
- pages
- 1244 - 1252
- publisher
- Oxford University Press
- external identifiers
-
- wos:000318105000014
- pmid:23230135
- scopus:84877130463
- pmid:23230135
- ISSN
- 1569-8041
- DOI
- 10.1093/annonc/mds613
- language
- English
- LU publication?
- yes
- id
- 2d65ed78-dd11-4d15-8e42-756ef980c1e1 (old id 3347307)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/23230135?dopt=Abstract
- date added to LUP
- 2016-04-01 10:34:01
- date last changed
- 2022-03-19 21:55:34
@article{2d65ed78-dd11-4d15-8e42-756ef980c1e1, abstract = {{BackgroundThe steroid-receptor coactivator amplified in breast cancer one (AIB1) is implicated to be a prognostic factor, although the results are not unanimous. Recently its effect was suggested to be modified by paired box 2 gene product (PAX2).Patients and methodsUsing immunohistochemistry (IHC) AIB1 and PAX2 were investigated in two cohorts of early breast cancer, including systemically untreated premenopausal lymph-node-negative women and pre- and postmenopausal women receiving tamoxifen.ResultsAIB1 scores were available for 490 patients and PAX2 scores were available for 463 patients. High AIB1 was a negative prognostic factor for distant disease-free survival (DDFS, P = 0.02) and overall survival (OS, P < 0.001) in systemically untreated women, while no prognostic effect was seen in the tamoxifen-treated cohort, indicating AIB1 to be a predictor of tamoxifen response. In systemically untreated patients, PAX2 was not a prognostic factor, nor did it modify the effect of AIB1. However, in ER-positive patients receiving tamoxifen, PAX2 appeared to be a positive prognostic factor in premenopausal patients, while a negative factor in postmenopausal. The interaction between the menopausal status and PAX2 was significant (P = 0.01).ConclusionsIn an independent cohort of low-risk premenopausal patients, we validate AIB1 as a negative prognostic factor, indicating AIB1 to be an interesting target for new anti-cancer therapies. The effect of PAX2 warrants further studies.}}, author = {{Alkner, Sara and Bendahl, Po and Grabau, Dorthe and Malmström, Per and Fernö, Mårten and Rydén, Lisa}}, issn = {{1569-8041}}, language = {{eng}}, number = {{5}}, pages = {{1244--1252}}, publisher = {{Oxford University Press}}, series = {{Annals of Oncology}}, title = {{The role of AIB1 and PAX2 in primary breast cancer: validation of AIB1 as a negative prognostic factor.}}, url = {{http://dx.doi.org/10.1093/annonc/mds613}}, doi = {{10.1093/annonc/mds613}}, volume = {{24}}, year = {{2013}}, }